Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Bronchiolitis Obliterans Syndrome
NCT02262299Phase 3Completed
- Sponsor
- Rigshospitalet
- Start
- May 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of pirfenidone in Bronchiolitis Obliterans Syndrome (BOS), sponsored by Rigshospitalet. Started May 2015; status: completed.
02
Drugs
pirfenidone
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT02262299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262299.